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Three Discipline Collaborative Radiation Therapy (3DCRT) Debate Series
Radiation Oncology is a highly multidisciplinary medical specialty, drawing 
significantly from three scientific disciplines - medicine, physics, and biology.  As 
40 a result, discussion of controversies or changes in practice within radiation 
oncology involves input from all three disciplines.  For this reason, significant 
effort has been expended recently to foster collaborative multidisciplinary 
research in radiation oncology, with substantial demonstrated benefit.(1,2)  In 
light of these results, we endeavor here to adopt this “team-science” approach to 
45 the traditional debates featured in this journal.  This article represents the third in 
a series of special debates entitled “Three Discipline Collaborative Radiation 
Therapy (3DCRT)” in which each debate team will include a radiation oncologist, 
medical physicist, and radiobiologist.  We hope that this format will not only be 
engaging for the readership but will also foster further collaboration in the science 
50 and clinical practice of radiation oncology.
1 Introduction
The advent of IMRT has significantly improved our ability to shape the dose 
distribution around tumors to spare adjacent normal tissue structures.  The 
treatment of tumors in the head and neck has benefited substantially from this 
55 capability since there are typically many adjacent normal tissue structures and 
due to the complex shapes of these tumors and organs at risk alike. However, 
creating more conformal treatment plans requires more accurate knowledge of 
the location and shape of patient anatomy.  Anatomical changes throughout the 
course of treatment can result in significant changes in the delivered dose 
60 distribution, thus prompting the creation of new plans during the course of 
treatment to adapt to these anatomical changes.  However, this necessitates a 
significant increase in workload for radiotherapy staff, increases the cost of care, 
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and provides no guarantee that the anatomy will be the same when the adapted 
plan is ready to be delivered.  Given the potential theoretical improvement in the 
65 delivered dose distribution, one may question whether all head and neck cancer 
patients should receive adaptive replanning.  This is the subject of this month’s 
3DCRT debate. 
Arguing for the proposition will be Drs. Emilie Soisson, Patrizia Guerrieri, and 
Sundaravadivel Balasubramanian. Emilie Soisson, PhD, is a medical physicist at 
70 the University of Vermont Medical Center.  She holds faculty appointments at the 
University of Vermont and McGill University.   She earned a PhD in Medical 
Physics at the University of Wisconsin where she was heavily involved in the 
clinical implementation of TomoTherapy, one of the first radiotherapy delivery 
systems specifically designed for adaptive radiotherapy.
75 Patrizia Guerrieri, MD, is board certified in Radiation Oncology in Italy and the 
USA and has a MS in Radiation Sciences. She currently practices at Allegheny 
Health Network in Pittsburgh and has special expertise in HDR brachytherapy, 
IMRT, and SBRT, for Head/Neck, Breast, and Gynecological cancers. She has 
authored publications, abstracts, and book chapters on gynecological 
80 brachytherapy, altered fractionation, and brachytherapy in the elderly and was a 
contributor to the Radiation Oncology Encyclopedia as well as “Principles and 
Practice of Radiation Oncology” by Perez and Brady.
Sundaravadivel Balasubramanian, PhD, is a cell biology researcher whose 
primary research focuses on cell signaling pathways altered during radiation 
85 treatment in the presence of cigarette smoke and e-cigarettes, and regulated 
breathing practices for symptom management in cancer and other conditions.  
He is also active in teaching radiation biology at the Medical University of South 
Carolina. 
Arguing against the proposition will be Drs. Anesa Ahamad, Jean Moran, and 
90 Michael Joiner.  Anesa Ahamad, MD, FRCR is an Associate Professor (pending, 
University of Miami) who trained in Manchester, UK and Houston. She balances 
patient-care with research. With interests in spatial targeting of tumors, 
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combined-modality tumor-ablation, and global-health, she has 138 publications, 
27 professional honors and awards, and 115 oral presentations.
95 Jean M. Moran, PhD, FAAPM is Professor and Co-Director of the Physics 
Division in Radiation Oncology at the University of Michigan.  Her research areas 
include patient safety and integration of technology advancements for 
appropriate patients. She is Co-Director of the Michigan Radiation Oncology 
Quality Consortium, a statewide registry to improve quality.  She serves AAPM 
100 and ASTRO through committee work.  
Michael C. Joiner, MA, PhD, Professor in the Division of Radiation Oncology 
(Department of Oncology) at Wayne State University, leads WSU’s radiobiology 
research. He focuses on how clinical radiotherapy can be made more effective 
using manipulations of the radiation delivery schedule. He discovered low-dose 
105 hyper-radiosensitivity, a major factor influencing the extent and type of signaling 
and DNA repair following X-ray exposure and therefore determining overall tumor 
effect and tissue toxicity.
2 Opening Statements
2.A Emilie Soisson, PhD; Patrizia Guerrieri, MD; Sundar Balasubramanian, 
110 PhD
With the exclusion of early stage true vocal cord cancer, the treatment of head 
and neck cancers with radiation implies the coverage of many radiation sensitive 
structures that are either abutting or in close proximity to the treatment volume.  
Intensity modulated radiation therapy (IMRT, VMAT, and TomoTherapy®) has 
115 been the standard of care in radiation therapy since the early 2000s and has 
allowed for the delivery of curative doses of radiation while sparing patients from 
heavy permanent adverse events at the level of the salivary glands, cervical 
esophagus, cochlea, spinal cord, glottis pharyngeal muscles, etc.  As a result, 
patients have substantially improved quality of life over the previous 3D 
120 conformal era. 
A known challenge in head and neck IMRT has been treatment plan robustness 
over the course of radiation therapy due to anatomical variations over the weeks 
of treatment, which can lead to increased delivered normal tissue doses over 
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those predicted in the original plan.  Radiation therapy impairs swallowing 
125 function by causing exudation, inflammation and slouching of the epithelium 
which, coupled with the taste impairment typical of the irradiation of salivary 
glands and oral cavity, is frequently linked to weight loss.   Even with IMRT, 
irradiation of the mucosa cannot be completely avoided due to disease extent, 
and weight loss must be considered over the course of radiation therapy.    In 
130 addition, there can be shrinkage of the gross disease or changes of shape or 
density of the organs at risk (OARs), which also may lead to volume reduction 
and increased normal tissue doses.  
Ultimately, the goal of adaptive replanning is to periodically change the treatment 
plan so that the delivered dose will more closely resemble the intended planned 
135 dose when treatment induced anatomical changes occur.  In the case of head 
and neck cancers, the main advantage is that the normal tissue tolerances can 
be respected as the tissue volume decreases by accounting for these changes in 
the treatment plan via incorporation of new imaging data.     With the widespread 
adoption of daily volumetric imaging, these adjustments could also happen as 
140 often as daily, making a “plan of the day” possible.  In addition, significant 
technological innovation on the part of the treatment planning system vendors 
has removed some of the technical hurdles that have made true daily adaptive 
therapy challenging to implement.  Unfortunately, the vendor-supplied workflows, 
usually involving automated deformable image registration and dose 
145 accumulation, have failed to become the standard of care due to the overhead 
associated with putting out a new plan, and performing the necessary validation 
and quality assurance.  
 
While, in theory, delivery accuracy only improves with increased plan frequency, 
150 there is limited clinical evidence that daily plan adaptation actually improves dose 
delivery in a clinically meaningful way for the majority of patients.  A prospective 
multi-institutional trial by Schwartz et al. (3) looking at adaptive radiotherapy for 
oropharyngeal squamous cell carcinoma showed that the majority of the 
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dosimetric benefits from adaptive planning can actually be achieved with just one 
155 or two mid-treatment replans.    
In fact, the clinical reality at this point is that most centers are using their adaptive 
planning workflows to perform only one, or a few, adapted plans. Generally, the 
plan is unanticipated, and a typical workflow follows:  A patient is under treatment 
and at some fraction something or somebody will trigger the need for a new plan.  
160 Examples of these triggers vary widely and could be something from a poorly 
fitting mask, to a physician noticing differences in anatomy upon pretreatment 
image review, to a more quantitative flag from a more sophisticated “in vivo” 
dosimetry system (i.e. EPID).  At this point, in most places, the patient would 
have to then be scheduled for a repeat simulation with the intent to create a new 
165 plan in an accelerated time frame (to avoid treating too many fractions with a 
potentially invalid plan).   In many centers, it means that this plan must take 
priority over other plans, disrupting the clinical workflow, and altering scheduling 
or staffing needs.   Many steps in the planning and QA may be rushed to allow 
for the short turnaround time, potentially compromising quality and safety. 
170 The proposition would remove this workflow bottleneck by making an a priori 
assumption that each head and neck patient will need at least one replan.  
Creation of an adapted plan at a minimum of one point in a patient’s treatment 
would be easily within the realm of possibility in most places.   Automated tools 
could be used to create the plan, the plan could even be screened by an 
175 automated system for dosimetric variation, and then, once flagged, the clinical 
staff would review this plan for clinical meaningful deviation.   After review of this 
scheduled replan, an informed decision could be made by the clinician to either 
proceed with the current plan or implement the adapted plan.   
Data gathered from this mandated replanning may also make it possible to come 
180 up with institution and patient specific predictive factors for anatomical change 
that will lead to significant dosimetric deviations during treatment.  In the future, 
these adaptive plans could potentially be scheduled at particular time-points 
based on the patient’s unique risk of requiring one.  In addition, scheduled 
Au
th
or
 M
an
us
cr
ip
t
This article is protected by copyright. All rights reserved
replanning will allow for the incorporation of information regarding treatment 
185 response obtained from other image modalities.  
It is well known that tumor oxygenation is an important factor in tumor cell kill. 
The distribution of oxygenated cells within a tumor is non-uniform over time due 
to changes in tumor vasculature and concomitant hypoxia. 18F-FDG PET is a 
widely used tool for mapping tumors based on metabolic activity, hypoxia, and 
190 cell proliferation, and has been used for adaptation during radiation therapy(4). 
Recent computer-based tumor response models suggest that tumor hypoxia 
based adaptation would be an effective way to reassess treatment dose (5). In 
addition, it has been suggested that a weekly reassessment would be as 
powerful as daily reassessment where the former could be less cumbersome 
195 operationally. While the use of 18F-FDG PET might be challenging due to the 
reactivity in areas of radiation-induced inflammation, this shortcoming could be 
avoided by using other tracers such as 18F-FMISO that are hypoxia specific (6).  
Therefore, using 18F-FDG/18F-FMISO PET imaging for assessing tumor 
metabolism, and using that information for IMRT would be an effective way to 
200 improve patients’ quality of life as well as reduce normal tissue toxicity.   Routine 
adaptive planning would provide a convenient time point for incorporation of new 
biological information in the patient’s therapy.
In conclusion, we are advocating that all head and neck cancer patients with 
intact tumors be scheduled for at least one replan over the course of treatment.  
205 Scheduled adaptive planning allows for incorporation of anatomical and 
biological information that can potentially lead to better patient outcomes while 
allowing for adequate allocation of clinical resources.  Timing of replanning 
events and the necessary plan evaluation criteria could be better informed 
through new data available as a direct result of implementation.
210 2.B Anesa Ahamad, MD; Jean Moran, PhD; Michael Joiner, PhD
There is a lack of evidence that adaptive radiotherapy (ART) will benefit all head 
and neck patients and ART could result in protocol deviations.  Protocol 
compliance has been demonstrated to be crucial for improving overall survival 
(7).  ART must address the diversity of tumor biology along with anatomical 
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215 changes and variations in patient setup.  For example, patients unlikely to benefit 
routinely from ART include those with early cancers of the glottis or the skin 
where only small volumes of tissues are treated. Subjecting all patients to 
adaptive planning wastes valuable resources.  The goal of ART for head and 
neck cancer is inadequately defined and an emphasis on ART may detract from 
220 incorporation of other information such as metabolic pre-treatment imaging and 
treatment considerations.  
Routine ART for head and neck cancer patients is just not doable.  There is an 
unmet need for robust and efficient tools for existing equipment which are 
available and able to be safely used in the broader community for patient care.   
225 Investigators have retrospectively demonstrated a correlation of changes on daily 
CBCT to xerostomia using a cumbersome process (8).  
Treatment time and the time between fractions are relevant for radiobiology. 
Thus, minimizing delivery time per fraction can improve effective dose on the 
tumor by as much as 10%, whilst avoiding more than one fraction per day can 
230 minimize toxicity (9). While tools are under development to make routine ART 
feasible, they are not yet perfected. Requirements include fast online imaging, 
accurate image registration and auto-segmentation tools, automated quality 
checks to ensure adequate review of contours, fast dose calculations, and 
decision support tools, incorporating knowledge of concurrent therapies such as 
235 sensitizers, to guide decisions about whether to implement a plan change. The 
accuracy of image registration must be assessed (10) and this is currently done 
by humans. Even with validated atlas-based auto-segmentation software, review 
and manual correction of target volumes and normal organs contours is still 
needed.(9)  The tools for ART are not yet robust, timely, and widely available.
240 While dose-reduction to regions where the tumor has regressed in HPV+ 
oropharyngeal cancers is being considered, its safety, in terms of cancer control 
or toxicity outcomes, has not yet been validated. Further, the calculated reduction 
of probability of late effects with decreased dose is quite small.(11)  Dose or 
volume reduction raises concern about leaving occult disease untreated.  It is not 
245 clear if tumor resolution on CT, MR or metabolic imaging corresponds to absence 
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of tumor cells.  Neither of these three modalities were shown to accurately 
predict pathologic complete response when studied in patients with breast cancer 
who were imaged following neoadjuvant chemotherapy and proceeded to 
surgery (FDG-PET/CT shows sensitivity of 38%-89% and specificity of 74%-
250 100%, MRI shows sensitivity of 35%-37% and specificity of 87%-89%).(12) In 
order to select patients with breast cancer for de-escalation of treatment by 
omitting surgery after neoadjuvant chemotherapy, the only satisfactory technique 
to determine absence of viable tumor cells was adequate sampling of the tumor 
bed using stereotactic image guided biopsies.(13) Therefore, by analogy with 
255 breast cancer, it may not be safe to shrink volumes or de-escalate dose in head 
and neck cancer without highly accurate verification of absence of tumor cells. 
There are far too many unanswered questions to justify routine ART.  What is the 
ideal imaging modality? It is unclear whether adaptation should be based on 
cone-beam CT, MRI, or metabolic imaging. Which patients would benefit from 
260 ART in head and neck cancer (14)? What is the optimal timing? Should it be 
performed every 5 fractions (15), within the first 10 fractions (16,17)? There are 
no randomized studies that show clinical benefit. How should treatment be 
altered when changes are detected?  Should we escalate dose to persistent 
tumor or de-escalate to regions without detectable tumor?  Studies of boosting 
265 the residual tumor volumes have shown an unacceptably high rate of severe late 
toxicity with persistent mucosal ulceration (18,19).  Therefore, boosting residual 
tumors is not ready for routine clinical practice. 
Finally, some patients may receive a greater benefit from a non-radiation therapy 
adaptation such as the addition of hypoxic sensitizers if hypoxia is detected and 
270 the use of immunotherapy.  
3 Rebuttal
3.A Emilie Soisson, PhD; Patrizia Guerrieri, MD; Sundar Balasubramanian, 
PhD
We agree with our opponents that there are many unanswered questions 
275 regarding the ideal clinical use of adaptive radiotherapy in the treatment of head 
and neck cancer.   It is also true that there is a lack of evidence to show that ART 
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will benefit all patients while there are also significant clinical hurdles to 
implementation.   However, as these technological hurdles lower, ART is only 
becoming more “doable”.  Routine plan adaptation through the smart 
280 implementation of new tools and techniques will provide clinical data required to 
answer some of these questions while allowing clinicians to gain clinical 
competency and confidence in their adaptive workflows. 
Since ideal patient selection for ART in head and neck cancer is not clear, why 
not give everybody the opportunity for ART through scheduled replanning for all?   
285 The statement we are arguing is only that adaptive replanning will be “scheduled” 
at least once.  It would be expected that not all patients will have enough 
anatomical or biological change to warrant implementation of a new plan.  By 
having a process in place to evaluate anatomical changes and subsequent 
dosimetric consequences, we will begin to gather clinical data that can later be 
290 used to better inform patient selection.   
Recent technological innovation in radiation therapy has been focused almost 
entirely on reducing the volume of tissue irradiated to high doses.  How can you 
fully realize the potential of these technologies without ART?   For example, 
proton therapy distributions are much less robust than photon therapy in the 
295 presence of anatomical variation (20).  The clinical viability of a technology such 
as the MR-LINAC is completely dependent on the ability to adapt plans when 
anatomical changes are seen (21).  This will also be true as more and more 
information regarding tumor biology is provided through novel imaging 
modalities. This scheduled replan is a good point to “check-in” on the tumor 
300 biology as we begin to embrace precision medicine in radiation therapy through 
well-designed clinical trials.
As our opponents point out, one of the main hurdles in the implementation of 
ART has been the availability of the required clinical resources. However, with 
the increased adoption of automated tools and improved pre-treatment image 
305 quality, many steps in the planning and plan evaluation process can be 
automated.   Significant improvements have been made in these tools and many 
investigators have identified streamlined methods to implement them. Validation 
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of automated deformable dose accumulation has always been challenging but in 
the scenario we propose, patient specific validation would only be required for 
310 patients in which significant anatomical change is detected.  Currently, ART IS 
happening in most clinics but all too often in an inefficient and risky way. If all 
patient plans were adapted, and the adaptive plan was scheduled, workflow 
bottlenecks that occur as a result of on-the-fly replanning could be avoided.
3.B Anesa Ahamad, MD; Jean Moran, PhD; Michael Joiner, PhD
315 The arguments presented by our opposition clearly demonstrate the 
impracticality of the notion: while scheduling adaptive planning is a great idea, 
they emphasize the burden of “overhead associated with putting out a new plan 
and performing the necessary validation and quality assurance”. These activities 
are cumbersome and wasteful, if an adaptive plan is not used, without a clear 
320 benefit to individual patients. Our colleagues cite an important, small pilot study 
(Schwartz et al) that showed minor dosimetric benefits for mid-treatment 
replanning but did not show clinical benefit nor was there scientific justification for 
the timing of replanning.    The ideal timing remains under study including new 
data emerging from daily on-treatment MRI imaging. 
325 The biology of the target is critical: the uncertainty of accurately locating the 
volume of residual viable tumor at the site of replanning is still unanswered. The 
specificity and sensitivity of 18F-FDG/18F-FMISO PET remains under study. 
Indeed, we agree it would be ideal to avoid the current unexpected decisions to 
replan, however as a community we lack the needed capabilities in routine 
330 practice to automate the process. The radiotherapy plans and online imaging of 
all head and neck cancer patients with intact tumors and nodes should be 
routinely analyzed by an intelligent program that can decide whether adaptive 
replanning is medically necessary. Until this technology is widely available, we 
are unable to replace the keen clinical observations by physicians, physicists and 
335 therapists that triggers replanning and the input from biologists to address 
fractionation considerations. Therefore, until more robust tools are available, 
clinical judgement and lessons learned from clinical trials remain best practice.
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